Elsevier

Gynecologic Oncology

Volume 38, Issue 3, September 1990, Pages 352-357
Gynecologic Oncology

Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

https://doi.org/10.1016/0090-8258(90)90072-SGet rights and content
Under a Creative Commons license
open archive

Abstract

There were 732 evaluable patients with primary, previously untreated, histologically confirmed stage I squamous carcinoma of the cervix with ⩾3-mm invasion. Of these, 645 had no gross disease beyond the cervix/uterus, had negative paraaortic lymph nodes, and had undergone a radical hysterectomy with pelvic lymphadenectomy. The 3-year disease-free interval (DFIs) for the 545 patients with negative pelvic nodes was 85.6%, and for the 100 with positive pelvic nodes, 74.4%. A large number of pelvic nodes involved with tumor was not correlated with a poorer prognosis; the DFIs were 72.1, 86.4, and 64.6% for one, two, and three or more positive pelvic nodes, respectively. DFI correlated strongly with depth of tumor invasion, both in absolute terms (mm) and infractional thirds. The DFI was 94.6% for ⩽5 mm, 86.0% for 6–10 mm, 75.2% for 11–15 mm, 71.5% for 16–20 mm, and 59.5% ⩾21 mm. In fractional terms, the DFI was 94.1% for superficial third, 84.5% for middle third, and 73.6% for deep third invasion. With respect to clinical tumor size, the DFIs were 94.8, 88.1, and 67.6% for occult, ⩽3 cm, and >3 cm, respectively. The DFI was 77.0% for those with positive capillarylymphatic spaces (CLS) and 88.9% for those with negative CLS. Tumor grade and parametrial status correlated with DFI. DFI was not significantly different for age, disease status of the surgical margins, tumor description (e.g., exophytic), quadrant involved with tumor, uterine extension, and keratinizing status of tumor cells. Clinical tumor size, CLS, and depth of tumor invasion were independent prognostic factors.

Cited by (0)

Presented at the annual meeting of the Society of Gynecologic Oncologists, San Francisco, CA, February 4–7, 1990.